Abstract：Objective To analyze the clinical effect of Apatinib in the treatment of advanced non-squamous non-small cell lung cancer.Methods Fifty patients with advanced non-squamous non-small cell lung cancer admitted to our hospital from December 2015 to February 2018 were selected as the subjects,and divided into control group and experimental group according to the numerical random method,with 25 cases in each group.The control group received conventional chemotherapy,and the experimental group received Apatinib.The total response rate,total adverse reaction rate,hospitalization time,and quality of life scores were compared between the two groups.Results The total remission rate of the experimental group was significantly higher than that of the control group,and the difference was statistically significant(P＜0.05).The total adverse reaction rate of the experimental group was significantly lower than that of the control group,and the difference was statistically significant(P＜0.05).The hospitalization time of the experimental group was significantly shorter than that of the group,and the quality of life score was significantly higher than that of the control group,the differences were statistically significant(P＜0.05).Conclusion The treatment effect of Apapitatin in patients with advanced non-squamous non-small cell lung cancer is significant.The incidence of adverse reactions is lower and the treatment effect is better.It can improve the quality of life of patients and shorten the length of hospital stay.Patients are more acceptable.It is worth promoting in clinical application.
苏晟田； 刘俊. 阿帕替尼治疗晚期非鳞非小细胞肺癌的临床效果[J]. 中国当代医药, 2019, 26(17): 54-56转60.
SU Sheng-tian； LIU Jun. Clinical effect of Apatinib in the treatment of advanced non-squamous non-small cell lung cancer. 中国当代医药, 2019, 26(17): 54-56转60.
Alhajj N，Chee CF，Wong TW，et al.Lung cancer：active therapeutic targeting and inhalational nanoproduct design[J].Expert Opin Drug Deliv，2018，15（12）：1223-1247.
[17]
Eichner LJ，Brun SN，Herzig S，et al.Genetic analysis reveals AMPK is required to support tumor growth in murine kras-dependent lung cancer models[J].Cell Metab，2018，29（2）：285-302.
[18]
Prorok PC，Wright P，Riley TR，et al.Overall and Multiphasic Findings of the Prostate，Lung，Colorectal and O-varian （PLCO）Randomized Cancer Screening Trial[J].Rev Recent Clin Trials，2018，13（4）：257-273.
京公网安备 11010502046607号